Sodium Valproate

Diana Johnson Excerpts

Thursday 29th October 2026 Commons Chamber

[The Minister for Public Health and Patient Safety (Dame Diana Johnson)]

May I too say how nice it is to see the Clerk of the House in his place? I pay tribute to him for his long service in this place, and wish him the very best for the next chapter.

I congratulate my hon. Friend the Member for Lancaster and Wyre (Cat Smith) on securing this important debate, and thank all hon. Members who have contributed on this sensitive and important topic. We have had important contributions from my hon. Friends the Members for Blaydon and Consett (Liz Twist), for Shipley (Anna Dixon) and for Washington and Gateshead South (Mrs Hodgson), and the hon. Member for Harrow East (Bob Blackman). You too, Madam Deputy Speaker, have been a long-standing supporter on this issue.

My hon. Friend the Member for Lancaster and Wyre has been working tirelessly for many years on behalf of her constituent Janet Williams and all the campaigners and the families, including Emma Murphy, to whom she referred. We need to ensure that the voices of women and families are heard, and that they are at the heart of our discussions and debates. I agree with my hon. Friend about the perseverance of women, and there is clear perseverance here. I have been very moved by the stories I have heard, including before coming into office, and the more I look into this matter, the more tragic it appears to be. I will watch that television programme on 9 November that my hon. Friend referred to.

As my hon. Friend would expect, since becoming the Minister for Public Health and Patient Safety, I have been briefed by officials on the Hughes report and the progress we have made so far. Of course, I am happy to meet my hon. Friend and the families affected. I am also determined to make progress on the Government’s response to the Hughes report, and I will of course work closely with devolved Governments in doing that because, as has been said, this affects all parts of the United Kingdom, so we need to work together. My predecessor, my hon. Friend the Member for Glasgow South West (Dr Ahmed), established a direct line with the Patient Safety Commissioner to start to drive this work forward. I think that was the right approach, and I look forward to meeting Professor Hughes shortly.

I am conscious that it has been more than two years since Professor Hughes published her report, and more than five years since the independent medicines and medical devices safety review was issued by Baroness Cumberlege. We know that the lives of women, children and their families have been profoundly changed. Their voices must be heard as we address these issues with the urgency demanded.

[James Naish (Rushcliffe) (Lab)]

My constituent Matthew Cox has foetal valproate syndrome. This time last year, he wrote to the Prime Minister. It took several months for him to get a response. He wrote again to No. 10 in March, and I wrote to the Health Secretary in July. There have been no responses, and the response that Matthew did receive was not an appropriate response for someone with learning difficulties. Will the Minister take Matthew’s case away specifically, and ensure that he gets the response he has been looking for? He and his mum welcome the hope that a new Labour Government brought on this; it is essential that we deliver for them.

[Dame Diana Johnson]

I will of course take that away. As a Minister, I have made it clear that we should respond in a timely way not only to Members of Parliament, but in other correspondence, and in a way in which people can understand what is being said to them. I absolutely take my hon. Friend’s point.

Moving on, we are determined to build a system that listens, that hears and that will act, and we need to do that with speed, compassion and proportionality. As someone who has fought hard for the compensation due to the victims of the infected blood scandal, I fully understand the strength of feeling on this matter, and I can also appreciate the frustrations of the families and the campaigners. This is a complex and sensitive issue that requires careful co-ordination across Government.

The support we offer to those who have suffered profound harm must be meaningful and responsive to their needs. The Government are clear that those affected have already waited far too long for answers. While a decision has not yet been taken to provide financial redress, my priority is to drive these discussions forward with greater urgency, while ensuring that any decisions we take are underpinned by a thorough assessment of the available options, with continued engagement across Government. Our discussions so far have considered the scope, affordability and practical challenges of a redress scheme, so I will say a few words about non-financial redress.

[Cat Smith]

I seek some clarity. The Minister says that the decision has not yet been made, yet a previous Secretary of State for Health and Social Care, the right hon. Member for Ilford North (Wes Streeting), told ITV that he was expecting financial redress by the end of this Parliament. Can the Minister just clarify that, because it seems inconsistent?

[Dame Diana Johnson]

My understanding of what the previous Secretary of State said is that he wanted to see progress within this Parliament. I am mindful of the Hughes report, which set out clear recommendations around redress, and I have just tried to set out that that is the avenue I am pursuing with some speed, looking at what the options are. I hope that that answers my hon. Friend.

[Liz Twist]

I know from the Minister’s previous work that she will be conscious of the issues, but we are two years on from the Hughes report, which made it clear that we need to act. This is an important issue, and it feels like a group—primarily of women—are being left to one side to wait their turn or bide their time. Can the Minister assure me that she will be in the Department, making sure that we get a real answer on financial and other redress? I am sure she will be doing that, but we need to see some action.

[Dame Diana Johnson]

I fully understand and appreciate the frustration, because it has been two years since the report was published. I will do my very best. I know that my predecessor, my hon. Friend the Member for Washington and Gateshead South, who is in her place, was also looking at what more we could do to speed up matters. I give an undertaking to this House that I will do my very best to make sure that we make progress on redress and all the recommendations in the Hughes report.

[Mrs Hodgson]

rose—

[Dame Diana Johnson]

I can see that my hon. Friend wants me to give way, and I am happy to.

[Mrs Hodgson]

I know that my right hon. Friend, with her experience of leading the infected blood campaign, is best placed to deliver for all these victims of mesh and valproate—maybe Primodos as well, although that was not covered in the Hughes report. I would like to add one other thing to her list, if I may, and that is payments from big pharma to the health sector. They really do have to be disclosed. At the moment, they are ambiguous and misleading, and lump sum payments can hide a multitude of payments. Does she agree that, to prevent future injustices, it is time for the Government to enact a statutory approach to payment transparency in the health sector?

[Dame Diana Johnson]

I am very happy to discuss that with my hon. Friend and see what we can do.

I want to deal with non-financial redress. It is important to recognise that people need support now. The Department is working with the NHS to put in place a range of measures to support the women and their families, alongside action to strengthen the safe prescribing of sodium valproate. In February, on the second anniversary of the Hughes report, the Minister for Secondary Care, my hon. Friend the Member for Bristol South (Karin Smyth), set out how the Department is addressing their needs by improving the clinical services and treatment that patients receive, commissioning further research and initiating long-term preventive measures. I would like to update colleagues on those initiatives.

First, on the improvements to services and treatment, the number of women who have been prescribed sodium valproate has gone down since 2018, although there is a cohort who have already been affected and require specific treatment. We must ensure that our healthcare system is shaped around their needs and experiences. Shortly after the Government came to office, NHS England began operating the foetal exposure to medicines pilot service in hospitals in Manchester and Newcastle, to which my hon. Friend the Member for Lancaster and Wyre referred. The project is providing multidisciplinary assessments, diagnosis and treatment planning, and its findings will inform the way we do this at a national level.

The proposed extension of the pilot project includes setting up a third site and an independent evaluation of the pilot, because we should not be marking our own homework. That should give us the evidence we need to determine whether a nationally commissioned service could be implemented across England. This approach balances the need to improve support for affected individuals and families with the requirement to ensure that any future national service is evidence-based, clinically effective and financially sustainable.

[Bob Blackman]

It is good news that the Minister is considering a national proposal. Will she undertake to have a meeting with the long-suffering victims of this scandal, who have been caring for their children for many years without support, in such desperate times, to show her commitment to doing what needs to be done for them? I think she will learn quite a lot from such a meeting.

[Dame Diana Johnson]

Of course I will. I would be very interested in doing that and learning more, and I am sure my office will be in touch with the hon. Gentleman about that.

Secondly, on research and development, we are working with clinicians from the pilot and other experts to see how we can improve the services available to affected patients.

Finally, on prevention, NHS England and the Medicines and Healthcare products Regulatory Agency have introduced strict measures to minimise valproate exposure during pregnancy, including pregnancy prevention programmes, and prescribing controls and specialist counselling for women who may become pregnant while taking the medication.

Let me close by again paying tribute to all the families whose lives have been changed forever by sodium valproate and the other issues that were set out in the Hughes report around pelvic mesh. I hope I have made clear how determined we are to respond to the Hughes report with the urgency and the compassion that those families absolutely deserve.

[Madam Deputy Speaker (Caroline Nokes)]

I was overseas when the tributes to the Clerk of the House were made last week, so I would just like to correct the Minister: the Clerk of the House cannot be very long serving, because he is clearly an incredibly young man and far too young to retire. I add my thanks to him for all the support and help he has given me in this role.

Question put and agreed to.